This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
100mg | $2850 | Check With Us |
250mg | $4500 | Check With Us |
500mg | $6750 | Check With Us |
Cat #: V10043 CAS #: 2216712-66-0 Purity ≥ 98%
Description: Elexacaftor (VX-445, WHO-11180; WHO11180; VX445; Kaftrio; Trikafta) is one of three components in the fixed-dose combination medication (Elexacaftor/tezacaftor/ivacaftor, trade name: Trikafta and Kaftrio) used in patients who have cystic fibrosis with a F508del mutation.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 597.65 |
---|---|
Molecular Formula | C26H34F3N7O4S |
CAS No. | 2216712-66-0 |
SMILES Code | O=C(C1=CC=C(N2N=C(OCC(C)(C)C(F)(F)F)C=C2)N=C1N3C(C)(C)C[C@H](C)C3)NS(=O)(C4=CN(C)N=C4C)=O |
Protocol | In Vitro | Elexacaftor (VX-445) is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function. Elexacaftor (VX-445) has the potential to treat cystic fibrosis. VX-445-Tezacaftor-VX-770 significantly improves Phe508del CFTR protein processing, trafficking, and chloride transport to a greater extent than any two of these agents in dual combination |
---|
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 1.6732 mL | 8.3661 mL | 16.7322 mL | 33.4644 mL |
5mM | 0.3346 mL | 1.6732 mL | 3.3464 mL | 6.6929 mL |
10mM | 0.1673 mL | 0.8366 mL | 1.6732 mL | 3.3464 mL |
20mM | 0.0837 mL | 0.4183 mL | 0.8366 mL | 1.6732 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.